LPCN — Lipocine Income Statement
0.000.00%
Last trade - 00:00- $16.37m
- -$1.57m
- $11.20m
- 38
- 37
- 17
- 19
Annual income statement for Lipocine, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 16.1 | 0.5 | -2.85 | 11.2 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 17.8 | 17 | 12.4 | 15.1 | 12.4 |
| Operating Profit | -17.8 | -0.855 | -11.9 | -17.9 | -1.16 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -21 | -0.634 | -10.8 | -16.4 | 0.009 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -21 | -0.634 | -10.8 | -16.4 | 0.008 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -21 | -0.634 | -10.8 | -16.4 | 0.008 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -21 | -0.634 | -10.8 | -16.4 | 0.008 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -6.45 | 0.384 | -2.09 | -3.1 | 0.002 |